BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?

Summary describes data showing a dampened clinical activity of PARP inhibitors in BRCA1 prostate cancer as compared to BRCA2 mutations. It proposes four biochemical hypotheses for this effect, but notes additional studies and meta-analyses are required to gain clearer insights.


Journal of Clinical Oncology